Correlation Engine 2.0
Clear Search sequence regions

Sizes of these terms reflect their relevance to your search.

Recent studies involving photosensitizing agents containing ruthenium (Ru) are interpreted as an indication that this approach might be useful for treatment of bladder cancer. The absorbance spectrum of such agents tends to be limited to wavelengths < 600 nm. While this can spare underlying tissues from photodamage, this will limit applications to instances where only a thin layer of malignant cells is present. Among the more potentially interesting results is a protocol that uses only Ru nanoparticles. Other issues in Ru-based photodynamic therapy are discussed including the limited absorbance spectrum, questions relating to methodology and a general lack of details concerning localization and death pathways. Copyright © 2023 Elsevier B.V. All rights reserved.


David Kessel. Critical PDT theory VII: The saga of ruthenium. Photodiagnosis and photodynamic therapy. 2023 Jun;42:103615

Expand section icon Mesh Tags

Expand section icon Substances

PMID: 37201769

View Full Text